Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes
Ryotaro Bouchi, Tatsuya Kondo, Yasuharu Ohta, et al.
Journal of Diabetes Investigation (2022) Vol. 14, Iss. 1, pp. 151-164
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY)
Daisuke Yabe, Kosuke Shiki, Gosuke Homma, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 12, pp. 3538-3548
Closed Access | Times Cited: 27
PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice
Daisuke Yabe, Yoshiyuki Hamamoto, Daiji Kawanami, et al.
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 11, pp. 1566-1577
Open Access | Times Cited: 7
Role of Triglyceride-Glucose Index in Type 2 Diabetes Mellitus and Its Complications
Ying Pan, Mengjie Zhao, Tiantian Song, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 3325-3333
Open Access | Times Cited: 6
Body mass index stratification optimizes polygenic prediction of type 2 diabetes in cross-biobank analyses
T Ojima, Shinichi Namba, Ken Suzuki, et al.
Nature Genetics (2024) Vol. 56, Iss. 6, pp. 1100-1109
Closed Access | Times Cited: 5
Glycaemic control efficacy of switching from dipeptidyl peptidase‐4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study (SWITCH‐SEMA 2 study)
Sho Furusawa, Hiroshi Nomoto, Hiroki Yokoyama, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 961-970
Closed Access | Times Cited: 11
Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U‐100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring
Yuji Kawaguchi, Yuriko Hajika, Maho Rinka, et al.
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 5, pp. 598-607
Open Access | Times Cited: 4
PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan
Ryo Suzuki, Hanan Amadid, Atheline Major‐Pedersen, et al.
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 8, pp. 1047-1056
Open Access | Times Cited: 4
Clinical efficacy and cost‐effectiveness of metformin in different patient populations: A narrative review of real‐world evidence
Anna Solini, Domenico Tricò
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S3, pp. 20-30
Open Access | Times Cited: 4
Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin
Juliana C.N. Chan, Aimin Yang, Natural Chu, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S3, pp. 55-74
Closed Access | Times Cited: 4
Short‐term outcomes of switching from GLP‐1 receptor agonists to tirzepatide in type 2 diabetes: A retrospective, observational study in clinical practice
Mari Matsushiro, Yuko Yamaguchi, Hitoshi Kuwata, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study
Manel Pladevall, Ryan Ziemiecki, Catherine B. Johannes, et al.
Diabetes Therapy (2025)
Open Access
Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan
Yuichiro Yano, Suguru Okami, Hiroshi Kanegae, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies
Ataru Igarashi, Hisateru Tachimori, Keiko Maruyama‐Sakurai, et al.
Advances in Therapy (2025)
Open Access
Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)
Yuki Oe, Hiroshi Nomoto, Kyu Yong Cho, et al.
BMC Endocrine Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G)
Mitsuru Ohsugi, Kosei Eguchi, Julie T Mortensen, et al.
Diabetes Research and Clinical Practice (2023) Vol. 203, pp. 110841-110841
Open Access | Times Cited: 6
Long‐term safety and efficacy of SGLT2 inhibitor use in older east Asians with type 2 diabetes
Yoshihiro Takahashi, Yutaka Seino, Daisuke Yabe
Journal of Diabetes Investigation (2023) Vol. 15, Iss. 1, pp. 63-66
Open Access | Times Cited: 6
Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study
Kohei Kaku, Y. Nakayama, Junko Yabuuchi, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 9, pp. 819-832
Open Access | Times Cited: 4
Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)
Yuki Oe, Hiroshi Nomoto, Kyu Yong Cho, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics
Tetsuaki Inokuchi, Yoshihide Fukumoto, Gendai Lee, et al.
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 9, pp. 1202-1210
Open Access | Times Cited: 1
Burden of Current Insulin Therapy and Expectations for Future Insulin Therapy: Results from INBEING, a Web-Based Survey in Japan
Yasuaki Hayashino, Satoshi Tsuboi, Yuiko Yamamoto, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 12, pp. 2537-2555
Open Access | Times Cited: 1
Treatment strategy for children and adolescents with type 2 diabetes-based on ISPAD Clinical Practice Consensus Guidelines 2022
Tatsuhiko Urakami
Clinical Pediatric Endocrinology (2023) Vol. 32, Iss. 3, pp. 125-136
Open Access | Times Cited: 3
Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg)
Masaki Okada, Hiroshi Bando, Noboru Iwatsuki, et al.
Asploro Journal of Biomedical and Clinical Case Reports (2023) Vol. 6, Iss. 2, pp. 116-123
Open Access | Times Cited: 3
Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
Tomoko Kato, Takaaki Murakami, Daisuke Yabe, et al.
Journal of Diabetes Investigation (2023) Vol. 14, Iss. 9, pp. 1038-1040
Open Access | Times Cited: 3
Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan
Daisuke Yabe, Munehide Matsuhisa, Yoko Takahashi, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 3, pp. 705-723
Open Access
Interplay of cardiovascular health and diabetes: Insights into weight management and risk reduction
Chih‐Yao Hsu, Hung‐Yuan Li
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 6, pp. 707-710
Open Access
Page 1 - Next Page

Scroll to top